NeuBase Therapeutics IncDUS NeuBase Stock Report

NeuBase Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases. The PATrOL-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. Its programs are NT-0100 in HD, NT-0200 in Myotonic Dystrophy Type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (mRNA). The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.